OBJECTIVE: To evaluate the effect and dose of @entity16960 given to pregnant @entity1 with @entity1211 . DESIGN: An observational study of pregnant @entity1 in Norway. SETTING: Delivery and haematological departments in Norway. POPULATION: Twenty @entity1 , aged 22-41 years, with @entity1211 verified by objective means. METHODS: @entity1 were treated with @entity16960 from diagnosis until delivery. Treatment was monitored with anti-activated factor Xa (anti-Xa) activity, and the dose was adjusted to achieve target 0.5-1.0 U/mL 2-3 hours post-injection. MAIN OUTCOME MEASURES: Anti-Xa activity and side effects. RESULT: None of the @entity1 suffered recurrent @entity1211 or major @entity548 complications. In 9 of 13 @entity1 starting with conventional dose of @entity16960 (100 iu/kg bd), dose escalation was necessary to reach target anti-Xa activity. None of the six @entity1 who started with 105-118 iu/kg bd required dose escalation. One @entity1 who started with 133 iu/kg bd required dose reduction. Bioaccumulation of @entity16960 was not observed. CONCLUSION: Our study suggests that @entity16960 may be used for the treatment of @entity1211 in pregnancy. Approximately 10-20% higher doses of @entity16960 may be needed as compared with non-pregnant individuals.

Low molecular weight heparin ( @entity16960 ) for the treatment of XXXX in pregnancy.

@entity1 :: ('9606', 'Species') :: ['women', 'Patients', 'woman', 'patients'] @entity16960 :: ('MESH:D017985', 'Chemical') :: ['dalteparin'] @entity1211 :: ('MESH:D054556', 'Disease') :: ['acute venous thromboembolism', 'venous thromboembolism'] @entity548 :: ('MESH:D006470', 'Disease') :: ['bleeding']
@entity1211 :: (MESH:D054556,Disease) :: ['venous thromboembolism']
